Company will market to pharmaceutical firms, governmental agencies, universities, and research institutes.
Expression Analysis entered a partnership with Complement Genomics, holding company of Geneblitz, to offer its genomic services for clinical trials and research to the U.K. market.
Geneblitz provides a range of services to the biotechnology sector, such as genotyping, DNA sequencing, forensic testing, and a number of toxicology and drug analysis protocols in addition to its own research programs in wound care.
“The partnership with Geneblitz provides us an established presence in the U.K., with an experienced service provider who operates with the same philosophy and similar quality standards and platforms,” says Steve McPhail, president and CEO of Expression.
The Geneblitz agreement with its emphasis on genome-wide association studies is reflective of Expression Analysis’ growing activity in this area, McPhail adds.
Expression Analysis’ genomic services include whole genome to focused-set gene expression and genotyping assays as well as sequencing services.
